Drugs / JOINTSTEM
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT03509025 | Feb 2017 → Dec 2020 | osteoarthritis, knee | R-Bio | Completed | No outcome recorded |
| Phase 2 | NCT02674399 | Feb 2016 → Mar 2018 | osteoarthritis, knee | Nature Cell Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02658344 | Jul 2015 → Nov 2016 | osteoarthritis, knee | R-Bio | Completed | Met primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04368806 | May 2021 → Dec 2026 expected | osteoarthritis, knee | Nature Cell Co. Ltd. | Recruiting | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT04427930 | Apr 2020 → Dec 2026 expected | osteoarthritis, knee | R-Bio | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03990805 | Jun 2019 → Dec 2020 | osteoarthritis, knee | R-Bio | Completed | Met primary |
| Phase not applicable2 trials | ||||||
| — | NCT04825730 | Dec 2023 → Dec 2028 expected | osteoarthritis, knee | R-Bio | Not yet recruiting | No outcome recorded |
| — | NCT04821102 | Jul 2023 → Aug 2024 | osteoarthritis, knee | R-Bio | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JointStem | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02674399 ↗ |
| Modality | Cell therapy | “it is classified as 'autologous cell therapy'” NCT02658344 ↗ |
| Route | Other | “The intra-articular injection of JOINTSTEM is expected to stimulate the regeneration and growth of cartilage” NCT02658344 ↗ |